Antimyelin antibodies as predictors of disability after clinically isolated syndrome

References

• Sawcer S, Hellenthal G, Pirinen M, Genetic risk and a primary role for cell- mediated immune mechanisms in multiple sclerosis. Nature 2011;476(7359):214–9.
   PubMed Web of Science ®Google Scholar
• Sellner J, Kraus J, Awad A, The increasing incidence and prevalence of female multiple sclerosis–a critical analysis of potential environmental factors. Autoimmun Rev 2011;10(8):495–502.
   PubMed Web of Science ®Google Scholar
• Miller D, Barkhof F, Montalban X, Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4(5):281–8.
   PubMed Web of Science ®Google Scholar
• Sellner J, Schirmer L, Hemmer B, Mühlau M. The radiologically isolated syndrome: take action when the unexpected is uncovered? J Neurol 2010;257(10):1602–11.
   PubMed Web of Science ®Google Scholar
• Sellner J, Weber MS, Vollmar P, The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon? CNS Neurosci Ther 2010;16(6):362–73.
   PubMed Web of Science ®Google Scholar
• Von Büdingen H-C, Gulati M, Kuenzle S, Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce ‘oligoclonal bands’. J Neuroimmunol 2010;218(1–2):134–9.
   PubMed Web of Science ®Google Scholar
• Cepok S, Rosche B, Grummel V, Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005;128(Pt 7):1667–76.
   PubMed Web of Science ®Google Scholar
• Kuenz B, Lutterotti A, Ehling R, Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE. 2008;3(7):e2559.
   Web of Science ®Google Scholar
• Gabibov AG, Belogurov AA Jr, Lomakin YA, Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. The FASEB J 2011;25(12):4211–21.
   PubMed Web of Science ®Google Scholar
• Wang H, Munger KL, Reindl M, Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008;71(15):1142–6.
   PubMed Web of Science ®Google Scholar
• Selter RC, Brilot F, Grummel V, Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 2010;74(21):1711–5.
   PubMed Web of Science ®Google Scholar
• Kerlero de Rosbo N, Honegger P, Lassmann H, Matthieu JM. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 1990;55(2):583–7.
   PubMed Web of Science ®Google Scholar
• Berger T, Rubner P, Schautzer F, Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349(2): 139–45.
   PubMed Web of Science ®Google Scholar
• Mayer MC, Meinl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord 2012; 5(3):147–59.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005;58(6):840–6.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444–52.
   PubMed Web of Science ®Google Scholar
• Greeve I, Sellner J, Lauterburg T, Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort. Acta Neurol Scand 2007;116(4):207–10.
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O'Riordan JI, A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346(3):158–64.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Lindberg RLP, Regeniter A, Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007;254(2):160–8.
   PubMed Web of Science ®Google Scholar
• Lim ET, Berger T, Reindl M, Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005;11(4):492–4.
   PubMed Web of Science ®Google Scholar
• Rauer S, Euler B, Reindl M, Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006;77(6):739–42.
   PubMed Web of Science ®Google Scholar
• Tomassini V, De Giglio L, Reindl M, Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007;13(9):1086–94.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Reindl M, Achenbach S, Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 2007;13(1):7–16.
   PubMed Web of Science ®Google Scholar
• Menge T, von Büdingen H-C, Lalive PH, Genain CP. Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. Eur J Immunol 2007;37(11):3229–39.
   PubMed Web of Science ®Google Scholar
• Zhou D, Srivastava R, Nessler S, Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006;103(50):19057–62.
   PubMed Web of Science ®Google Scholar
• Menge T, Lalive PH, von Büdingen HC, Genain CP. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. J Neuroinflammation 2011;8:161.
   PubMed Web of Science ®Google Scholar
• O'Connor KC, Appel H, Bregoli L, Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005;175(3):1974–82.
   PubMed Web of Science ®Google Scholar
• Klawiter EC, Piccio L, Lyons J-A, Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Arch Neurol 2010;67(9):1102–8.
   PubMedGoogle Scholar
• Brilot F, Dale RC, Selter RC, Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66(6):833–42.
   PubMed Web of Science ®Google Scholar
• Lalive PH, Häusler MG, Maurey H, Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011;17(3):297–302.
   PubMed Web of Science ®Google Scholar
• Vogt MHJ, Teunissen CE, Iacobaeus E, Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80(10):1110–5.
   PubMed Web of Science ®Google Scholar
• Lim ET, Petzold A, Leary SM, Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. J Neg Results Biomed 2004;3:4.
   PubMedGoogle Scholar